research use only

BrdU (Bromodeoxyuridine, 5-BrdU) Thymidine Nucleoside Analog

Cat.No.S7918

BrdU (Bromodeoxyuridine) is a nucleoside analog that competes with thymidine for incorporation into DNA, and used in the detection of proliferating cells.
Jump to

Quality Control

Batch: Purity: 99.99%
99.99

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse neural precursor cells Antiproliferative assay Antiproliferative activity against mouse neural precursor cells by MTT assay, EC50=2.045μM 17417631
murine leukemia cells Growth inhibition assay In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells, IC50=12μM 11101356
murine leukemia cells Growth inhibition assay In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]Leu., IC50=20μM 11101356
murine leukemia cells Growth inhibition assay In vitro growth inhibition of L5178Y-Parental murine leukemia cells, IC50=26μM 11101356
murine leukemia cells Growth inhibition assay In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]-Thd., IC50=26μM 11101356
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 61 mg/mL (198.63 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 3 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 307.1 Formula

C9H11BrN2O5

Storage (From the date of receipt) 3 years -20°C(in the dark) powder
CAS No. 59-14-3 Download SDF Storage of Stock Solutions

Synonyms 5-Bromo-2'-deoxyuridine, BUdR SMILES C1C(C(OC1N2C=C(C(=O)NC2=O)Br)CO)O

Read more about storage stability CAS number SMILES

Mechanism of Action

In vitro

Bromodeoxyuridine (BrdU) induces a progressive, dose-responsive suppression of cancer cell line and cancer stem cell population expansion in RG2 rat glioma cells, and alters the cell cycle profile in H9 cells and BJ fibroblasts.

This compound is stably integrated into the DNA, and thus can be used in assessment of cell proliferation and other cell procession.

In vivo

In rat glioma RG2 tumor model, BrdU (300 mg/kg, i.p. or 0.8 mg/ml, p.o.) significantly slows tumor progression.

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04365205 Recruiting
Asthma
University Hospital Bordeaux
2020-09-23 --
NCT02654925 Completed
Obesity
University of Colorado Denver
2016-03 --
NCT01407211 Unknown status
Relapsing Remitting Multiple Sclerosis
Tehran University of Medical Sciences
2011-04 Phase 4
NCT01414972 Unknown status
Atherosclerosis
Tehran University of Medical Sciences
2010-05 Phase 4
NCT01225289 Completed
Relapsing Remitting Multiple Sclerosis
Tehran University of Medical Sciences
2009-10 Phase 4
NCT00042250 COMPLETED
Hematologic Malignancies
M.D. Anderson Cancer Center
1992-05

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map